Favipiravir for symptomatic COVID-19: A nationwide observational cohort study

INTRODUCTION: Favipiravir, an antiviral agent with activity against SARS-CoV-2, was made available to hospitals in Japan for off-label use among COVID-19 patients between 2020 and 2021. METHODS: A nationwide observational cohort study was conducted on patients who received favipiravir as part of cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Yohei, Ishihara, Takuma, Banno, Sumi, Ando, Masahiko, Kondo, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597580/
https://www.ncbi.nlm.nih.gov/pubmed/36307058
http://dx.doi.org/10.1016/j.jiac.2022.10.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597580/
https://www.ncbi.nlm.nih.gov/pubmed/36307058
http://dx.doi.org/10.1016/j.jiac.2022.10.008

Ejemplares similares